{"filings":[{"id":2079159,"accession_number":"0001193125-26-335150","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-08-05T20:15:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $33.7M, product sales down 19% YoY; withdraws 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales $27.2M (-19% YoY); LAL units 24,917; LDD units 12.","Net loss $(12.1)M ($(0.29)/share); adjusted net loss $(4.6)M ($(0.11)/share).","New CEO Aziz Mottiwala appointed; Alcon collaboration with up to $200M in payments.","Next-gen Light Adjustable Technology platform announced; 2026 guidance withdrawn.","Cash and investments $208.8M as of June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1665037,"accession_number":"0001193125-26-304812","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-07-15T20:23:33+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"RxSight appoints Aziz Mottiwala as CEO; founder Ron Kurtz becomes CMO effective July 20, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mottiwala receives $750k base salary, 90% target bonus, and $14M in equity ($2M option + $12M RSU).","Kurtz transitions to CMO with $740k salary, up to 100% bonus, four $370k retention bonuses, and 500k RSU award.","Kurtz resigns from Board; Mottiwala appointed to fill vacancy as Class II director.","Board adopts 2026 Inducement Plan reserving 3.5M shares for new-hire equity grants.","Company states it is not updating previously communicated financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1471798,"accession_number":"0001193125-26-296200","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-07-06T20:15:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight lowers FY2026 sales guidance, reports Q2 prelim revenue $32-34M, Alcon collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2026 revenue $32-34M, including $5-7M from Alcon collaboration; sales ~$27M (24,917 LAL units, 11 LDD units).","FY2026 sales guidance lowered to $110-120M (from $120-135M); total revenue guidance $140-160M including collaboration revenue $30-40M.","Gross margin guidance raised to 73-75% (from 70-72%); operating expense guidance unchanged at $150-160M.","Strategic collaboration with Alcon to develop light-adjustable presbyopia-correcting IOLs; pipeline includes next-gen LAL, LAL+, LAL Toric.","Cash and investments ~$209M as of June 30, 2026; cites competitive trialing as headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1471797,"accession_number":"0001193125-26-296201","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-07-06T20:15:17+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"RxSight and Alcon enter collaboration to develop adjustable PCIOLs; $60M upfront, up to $140M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["RxSight receives $60M upfront; potential $70M feasibility milestone, $30M FDA submission milestone, $40M approval milestone.","Alcon to pay 30% royalties on net sales of collaboration products; RxSight to develop and manufacture, Alcon to commercialize globally.","Collaboration combines RxSight's light-adjustable technology with Alcon's presbyopia-correcting IOL optics for post-operative fine-tuning.","Agreement includes non-exclusive licenses; RxSight retains U.S. regulatory approvals and will supply LDD devices.","Deal could accelerate adoption of adjustable IOLs; Alcon is global eye care leader (SIX/NYSE: ALC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1084721,"accession_number":"0001193125-26-272688","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-06-16T20:30:15+00:00","items":["5.07"],"status":"ready","headline":"RxSight stockholders re-elect three Class II directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["William J. Link re-elected with 21,086,793 votes for; Robert Warner with 15,667,180; Shweta Singh Maniar with 13,850,389.","Advisory vote on executive compensation approved: 21,236,615 for, 2,742,189 against.","Ratification of Ernst & Young as independent auditor for FY 2026: 33,062,585 for, 92,653 against.","Meeting quorum of 33,299,192 shares (80.4% of outstanding) present at June 16, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91365,"accession_number":"0001193125-26-208912","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.","20 Light Delivery Devices sold in Q1, expanding installed base to 1,154 units.","Net loss of $(15.9)M ($(0.38)/share) vs $(8.2)M ($(0.20)/share) in Q1 2025.","Cash, equivalents and short-term investments totaled $217.9M as of March 31, 2026.","2026 revenue guidance reiterated at $120M-$135M; gross margin 70%-72%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":30893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101390,"accession_number":"0001193125-26-115965","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K/A","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RxSight discloses CFO's sign-on bonus of $169K and corrects option vesting schedule","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Mark Wilterding's sign-on bonus determined at $169,348.10 and paid March 13, 2026.","Sign-on bonus paid less payroll deductions and required withholding, per employment letter.","Option vesting corrected: 25% vests on Jan 11, 2027 anniversary, balance monthly over next 3 years.","Option fully vested after 4 years from Jan 11, 2026, subject to continued employment.","Amendment filed to prior 8-K dated Jan 12, 2026 regarding CFO appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101392,"accession_number":"0001193125-26-071516","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight reports Q4 revenue down 19% YoY; 2025 net loss $(38.9M); issues weak 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $32.6M (-19% YoY); LAL revenue -1%, LDD revenue -72%.","FY 2025 revenue $134.5M (-4% YoY); net loss $(38.9M) vs $(27.5M) in 2024.","LAL unit sales 109,615 (+12% YoY); LDD installed base 1,134 units; procedures >300,000 since launch.","FY 2026 guidance: revenue $120-135M (down YoY); gross margin 70-72%; op-ex $150-160M.","Adjusted net loss per share $(0.18) in FY 2025 vs $(0.07) in FY 2024; cash $228.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":134479000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101391,"accession_number":"0001193125-26-010478","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.","LAL procedure volume 28,611 in Q4 (+10% QoQ) and 109,615 in FY2025 (+12% YoY).","Installed LDD base reached 1,134 as of Dec 31, 2025 (25 LDDs sold in Q4).","Cash & short-term investments ~$228.1M as of Dec 31, 2025.","Mark Wilterding appointed CFO effective Jan 11, 2026, replacing Shelley Thunen (consulting role)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":134479000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117755,"accession_number":"0001193125-25-331151","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"RxSight enters CFO transition agreement with Thunen; reaffirms 2025 outlook","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shelley Thunen transitions from CFO; transition and consulting agreements executed effective Dec 23, 2025.","Company reaffirms full-year 2025 outlook unchanged by CFO transition.","Transition was previously announced; material terms incorporated by reference from Dec 22, 2025 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117754,"accession_number":"0001193125-25-328951","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"RxSight CFO Shelley Thunen to transition; consulting agreement through Dec 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Shelley Thunen to depart by Jan 31, 2026 or upon appointment of successor; will serve as consultant thereafter.","Consulting agreement provides $15,000 monthly retainers for Jan-Mar 2026, plus $500/hour for services.","Thunen remains eligible for fiscal 2025 annual cash bonus based on corporate performance.","Outstanding stock options continue vesting during consulting term ending Dec 31, 2026.","No successor named; Ron Kurtz cites nearly decade of service; company has 1,100+ LDDs and 250k+ procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117753,"accession_number":"0001193125-25-326889","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RxSight appoints Eric Weinberg as Chief Business Development Officer, Scott Gaines as Chief Customer Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Weinberg appointed Chief Business Development Officer, transitioning from Chief Commercial Officer on December 18, 2025.","Scott Gaines appointed Chief Customer Officer, overseeing Company's U.S. commercial organization.","Both appointments effective December 18, 2025, per Board decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117752,"accession_number":"0001193125-25-266938","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q3 revenue down 14% YoY to $30.3M; net loss widens to $9.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $30.3M (-14% YoY); LAL volume up 6% but LDD placements down 68%.","Net loss $(9.8)M ($(0.24)/share) vs $(6.3)M ($(0.16)/share) in Q3 2024.","Adjusted net loss $(1.7)M ($(0.04)/share) vs adjusted net gain $0.2M prior year.","Narrowed FY2025 revenue guidance to $125-130M (prior $120-130M); raised gross margin guidance to 76-77%.","Cash and investments $227.5M, unchanged from June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":101871000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134194,"accession_number":"0001111485-25-000003","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K/A","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RxSight appoints director Cohen to Compensation and Audit Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raymond W. Cohen appointed to Compensation and Audit Committees effective August 14, 2025.","Compensation Committee now: Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, Raymond W. Cohen.","Audit Committee now: Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D, Raymond W. Cohen.","This amendment updates the July 31, 2025 8-K that reported Cohen's Board appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134197,"accession_number":"0000950170-25-105027","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.","Net loss $(11.8)M ($(0.29)/share) vs $(6.1)M loss a year ago; adjusted net loss $(3.2)M.","Installed LDD base grew 34% to 1,084 units; FDA approved expanded LAL diopter range to -2.0 to +3.0.","Launched Light Adjustable Lens system in South Korea and Singapore; commercial team realigned.","Reaffirmed FY2025 revenue guidance $120M-$130M, gross margin 72%-74%, opex $145M-$155M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":71531000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134196,"accession_number":"0000950170-25-102065","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RxSight appoints former Axonics CEO Raymond Cohen to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raymond W. Cohen, former CEO of Axonics (sold to BSX for $3.7B), appointed to RxSight board as Class I director effective July 31, 2025.","Cohen also led SoniVie sale to Boston Scientific for $600M; has over 40 years medtech experience.","Will serve until 2028 annual meeting; receives standard non-employee director compensation including $277,500 initial RSU grant.","Press release issued August 4, 2025; no other changes to board or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134195,"accession_number":"0000950170-25-094588","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.","FY2025 revenue guidance slashed to $120-130M (from $160-175M), implying 7-14% decrease from 2024.","Gross margin guidance raised to 72-74% (from 71-73%); operating expense guidance $145-155M, up 7-14% YoY.","Installed LDD base of 1,084 units (+34% YoY); management cites underperformance and plans to refocus commercial strategy.","Cash $227.5M as of June 30, 2025, down $1.8M from March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":71531000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150973,"accession_number":"0000950170-25-081636","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RxSight shareholders re-elect three Class I directors, approve say-on-pay and auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of ~79.2% (32.18M of 40.62M shares represented) at June 3 annual meeting.","Ron Kurtz, J. Andy Corley, and Juliet Tammenoms Bakker re-elected as Class I directors.","Say-on-pay advisory vote passed with 22.37M for, 3.32M against, 98.7K abstain.","Ratification of Ernst & Young as auditor for FY2025 approved with 31.95M for, 92K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150972,"accession_number":"0000950170-25-065655","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q1 revenue $37.9M (+28% YoY); LAL volume up 36%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $37.9M (+28% YoY); LAL revenue +37%, LDD revenue +8%.","Net loss $(8.2M) or $(0.20)/share; adjusted net loss $(1.1M) or $(0.03)/share.","27,579 LALs sold (+36% YoY); 73 LDDs; installed base 1,044 (+43% YoY).","Gross margin 74.8% vs 70.1% YoY; cash $229.3M at quarter end.","Reiterated FY2025 guidance: revenue $160-175M, GM 71-73%, OpEx $150-160M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":37895000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150971,"accession_number":"0000950170-25-049797","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight preliminary Q1 revenue $37.9M (+28% YoY); cuts FY2025 guidance to $160M-$175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue ~$37.9M, up 28% YoY but down 6% QoQ; LAL procedure volume 27,579 (+36% YoY).","LDD installed base reached 1,044 as of March 31, 2025, a 43% increase from 732 a year earlier.","FY2025 revenue guidance lowered to $160M-$175M (from $185M-$197M); operating expense guidance cut to $150M-$160M.","Stock-based compensation expected to be $27M-$30M, up from prior $22M-$25M; cites premium IOL market headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":37895000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169877,"accession_number":"0000950170-25-026651","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).","Q4 net loss $(5.9)M vs $(9.2)M; adjusted net earnings $1.3M ($0.03/share) vs adjusted loss $(4.8M).","LAL procedure volume 29,069 units (+61% YoY); LDD installed base 971 (+46% YoY).","FY2025 guidance: revenue $185-197M (32-41% growth), gross margin 71-73%, operating expenses $165-170M.","Cash and investments $237.2M; no debt mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":139927000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169876,"accession_number":"0000950170-25-004478","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).","LAL procedure volume Q4 29,069 (+61% YoY); FY 98,055 (+79% YoY).","LDD installed base 971 as of Dec 31 (+46% YoY); cash & investments $237.2M.","2025 revenue guidance $185M-$197M (32-41% growth); gross margin 71-73%.","Preliminary results subject to audit; audited FY2024 & unaudited Q4 due Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":139927000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186929,"accession_number":"0000950170-24-123322","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q3 revenue $35.3M (+59% YoY); raises FY revenue guidance to $139-140M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.3M, up 59% YoY; LAL procedures 24,554 (+80%), LDD installed base 888 (+51%).","Gross margin 71.4% vs 61.9% YoY; net loss narrowed to $6.3M ($0.16/sh) from $12.4M ($0.35/sh).","Adjusted net earnings $214K ($0.00/diluted) vs adjusted loss $6.9M ($0.19/sh) a year ago.","FY2024 revenue guidance raised to $139-140M top of prior range; gross margin guided 70-71% (up from 68-70%).","Cash & equivalents $237.1M at Sept 30, 2024 vs $233.3M at June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":99713000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203470,"accession_number":"0000950170-24-090744","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.","Net loss improved to $(6.1)M ($(0.16)/share) from $(13.8)M ($(0.40)/share) in Q2 2023; adjusted net income $0.0M.","Installed LDD base reached 810 units (+55% YoY); 78 LDDs sold in Q2 (+16% YoY).","FY2024 revenue guidance raised to $139-140M (56-57% growth) from prior $132-137M; gross margin guidance unchanged 68-70%.","Cash $233.3M at June 30, 2024, includes $107.5M net proceeds from public offering closed May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":64399000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219907,"accession_number":"0000950170-24-069895","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RxSight shareholders re-elect three Class III directors, approve say-on-pay, one-year frequency, and E&Y ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class III directors re-elected: Julie B. Andrews, Robert J. Palmisano, Tamara R. Fountain.","Say-on-pay approved: 22.6M for, 1.1M against, 0.4M abstain.","Advisory vote on frequency: one-year option favored with 20.5M votes; company will hold annual say-on-pay.","Ratification of Ernst & Young as independent auditor for FY 2024: 29.9M for, 46k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219906,"accession_number":"0001193125-24-135328","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"RxSight prices $100M public stock offering at $56/share for commercial expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.","Net proceeds expected ~$93.2M after underwriting discount and estimated offering expenses.","Proceeds to fund commercial/marketing expansion (including international), product development, R&D, and working capital.","Offering expected to close May 13, 2024, subject to customary closing conditions.","Directors and executive officers subject to 60-day lock-up restrictions on their shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219905,"accession_number":"0000950170-24-053553","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).","Gross margin expands to 70% from 59% on favorable mix and lower production costs.","Net loss narrows to $9.1M ($0.25/share) from $13.2M ($0.42); adjusted loss $4.4M ($0.12).","Raises FY2024 revenue guidance to $132-137M (from $128-135M) and gross margin to 68-70%.","Cash remains strong at $125.4M, down slightly from $127.2M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":29512000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219904,"accession_number":"0000950170-24-046558","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"RxSight enters new lease and amends two leases for Aliso Viejo facilities with ~$10.8M future minimum payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 26,825 sq ft lease at 125 Columbia: base rent $41,579/mo, term June 1, 2024–Jan 31, 2031, with two 60-month renewal options.","Amended 5 Columbia lease: extended 70 months from April 2025; base rent $30,701/mo with escalations from April 2027.","Amended 100 Columbia lease: extended 76 months from Oct 2024; base rent $64,843/mo with escalations from Oct 2025.","Future minimum lease payments total ~$10.8M: $0.2M in 2024, $1.4M in 2025, $1.6M in 2026, $1.8M in 2027/2028, $4.0M thereafter.","Leases align end dates to Jan 2031 across four facilities and add manufacturing capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239655,"accession_number":"0000950170-24-022053","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q4 revenue $28.6M (+78% YoY); LAL volume +98% YoY; guides FY2024 rev $128-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $28.6M, up 78% YoY, with 77 LDDs sold and 18,071 LALs (+98% YoY).","Full year 2023 revenue $89.1M (+82% YoY); net loss $(48.6)M vs $(66.8)M in 2022.","Q4 gross margin 62% vs 46% YoY; full year gross margin 60% vs 44%.","FY2024 guidance: revenue $128M-$135M (44-52% growth); gross margin 65-67%; opex $125M-$128M.","Cash and investments $127.2M at Dec 31; Q4 adjusted net loss $(4.8)M or $(0.13)/share."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":89077000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239654,"accession_number":"0000950170-24-002636","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q4 rev ~$28.6M (+78% YoY); FY2023 rev ~$89.1M (+82%); guides FY2024 rev $128-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 rev ~$28.6M (+78% YoY) driven by 77 LDD placements and 18,071 LALs sold.","FY2023 rev ~$89.1M (+82% YoY); 666 LDD installed base; 54,873 LALs sold.","Cash and investments ~$127.2M as of Dec 31, 2023.","FY2024 revenue guidance of $128-135M (+44-52% YoY); gross margin 65-67%.","Expects 2024 operating expenses $125-128M; non-cash expenses $22-25M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":89077000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257166,"accession_number":"0000950170-23-062039","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q3 revenue up 76% to $22.2M; raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $22.2M (+76% YoY); net loss $(12.4)M, EPS $(0.35); adjusted net loss $(6.9)M, adj. EPS $(0.19)","Sold 66 LDDs (installed base 589, +72% YoY); LAL procedure volumes 13,657 (+107% YoY)","Raised FY2023 revenue guidance to $85-87M (prior $81-86M); gross margin guidance 60-61% (prior 58-60%)","Eliminated remaining $20M term loan; expects to reduce annualized interest expense by ~$5.6M","Raised $11.7M net via ATM facility; cash/short-term investments $131.9M at quarter end"],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":60497000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274503,"accession_number":"0000950170-23-039068","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $20.8M (+83% YoY); raises FY2023 guidance; pays off $40M debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $20.8M (+83% YoY); net loss $(13.8)M vs $(16.7)M last year.","Raised FY2023 revenue guidance to $81-86M (prior $79-84M); gross margin 58-60%.","LAL procedure volumes 12,622 (+134% YoY); LDD installed base 523 (+78% YoY).","Paid off $40M debt in Q2 and early Q3, eliminating ~$5.6M annual interest expense.","Raised ~$31.3M net from ATM in Q2 and early Q3 to fund debt repayment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":38299000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274502,"accession_number":"0000950170-23-031482","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["1.01","1.02","2.03","3.03","9.01"],"status":"ready","headline":"RxSight refinances debt: $20M new loan at lower rate, extends maturity to 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sold 834,748 common shares via ATM for $19.4M net proceeds; used $20M to repay existing debt.","New $20M loan from Oxford Finance at floating rate ~11.5% vs prior ~14.0%, saving ~$1.7M in H2 2023 interest.","Added up to $40M in additional borrowing capacity in four tranches through H1 2025, subject to revenue milestones.","Principal payments deferred to Aug 2026 (or Aug 2027 if IP not pledged) vs previous Apr 2025; maturity extended to Jun 2028.","Final payment fee of 5% of original principal; negative pledge on intellectual property."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291782,"accession_number":"0000950170-23-025787","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RxSight shareholders re-elect three Class II directors, approve charter amendment, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected William J. Link, Robert Warner, and Shweta Singh Maniar as Class II directors with 24.2M, 21.9M, and 21.2M votes for, respectively.","Approved certificate of incorporation amendment for officer exculpation under Delaware law: 22.2M for, 2.2M against.","Ratified Ernst & Young as independent auditor for FY2023: 29.5M for, 3,150 against.","87.2% of outstanding shares (29.6M of 33.97M) represented at the June 1, 2023 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291781,"accession_number":"0000950170-23-019669","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q1 revenue $17.5M (+96% YoY); raises FY2023 revenue and margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.5M, up 96% YoY; gross margin improved to 59% from 42%.","Net loss $(13.2)M ($0.42/share) vs $(17.6)M loss a year ago; adjusted loss $(0.31)/share.","LAL procedure volumes 10,523 (+153% YoY); LDD installed base grew to 456 units (+85% YoY).","Raised ~$64.5M net proceeds from equity offerings; cash & investments $153.9M.","FY2023 guidance raised: revenue $79-84M (prior $78-83M); gross margin 56-58% (prior 52-54%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":17489000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312553,"accession_number":"0000950170-23-006234","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q4 revenue $16.1M (+91% YoY); FY22 revenue $49.0M (+117%); guides FY23 rev $78-83M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $16.1M, up 91% YoY; LAL procedure volumes up 208% to 9,123 units; LDD installed base 400 (+94% YoY).","Full year 2022 revenue $49.0M, up 117% YoY; sold 195 LDDs and 25,284 LALs.","FY23 revenue guidance $78-83M (59-69% growth); gross margin guidance 52-54% (up from 43.5% in FY22).","Net loss Q4 $(15.6)M ($0.56 loss per share); adjusted net loss $(12.6)M ($0.45 loss per share).","Completed public offering of 4.6M shares (including underwriter option) at $12.50/share in Feb 2023, raising ~$57.5M gross."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312552,"accession_number":"0001193125-23-027742","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"RxSight prices public offering of 4M shares at $12.50 each for ~$50M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4,000,000 shares of common stock at $12.50 per share; gross proceeds ~$50.0M, net ~$46.7M.","Underwriters granted 30-day option to purchase up to 600,000 additional shares at same price.","Offering expected to close February 10, 2023; BofA Securities sole bookrunning manager.","Net proceeds to fund commercial expansion, product development, R&D, and working capital.","Officers and directors subject to 90-day lock-up restrictions on share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312551,"accession_number":"0000950170-23-000394","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"RxSight reports preliminary Q4 2022 revenue $16.1M, up 91% YoY; full-year $49.0M, up 117%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $16.1M (+91% YoY); 57 LDDs sold, installed base 400 LDDs as of Dec 31, 2022.","Full-year 2022 revenue $49.0M (+117% YoY); 25,284 LALs sold.","Preliminary cash, equivalents & short-term investments $105.8M, including $6.0M ATM net proceeds.","Management expects continued growth in 2023; audited results targeted for early March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":49005000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331074,"accession_number":"0000950170-22-026362","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"RxSight amends bylaws to update director nomination procedures and conform to Delaware law","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended bylaws require stockholders nominating directors to provide evidence of compliance with Rule 14a-19 at least five business days before meeting.","Revised stockholder meeting procedures and board action by written consent to conform to recent DGCL amendments.","Updated provisions regarding directors, Board committees, and officers; made ministerial and conforming changes.","Bylaw amendments effective December 9, 2022, approved by Board on recommendation of Corporate Governance and Nominating Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331073,"accession_number":"0000950170-22-022592","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q3 revenue $12.6M (+118% YoY); raises FY22 guidance to $47-48M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 revenue of $12.6M, up 118% YoY; LDD installed base reached 343 units (113% YoY increase).","Sold 6,595 LALs (+234% YoY); gross margin improved to 42.5% vs 23.2% in Q3 2021.","Raised FY2022 revenue guidance to $47-48M (from $44-46M); gross margin guidance raised to 41-43%.","Net loss of $(16.8)M or $(0.61)/share vs $(12.7)M or $(0.68)/share in Q3 2021.","Cash & investments $112.8M; long-term debt $40.0M; operating expense guidance lowered."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":32917000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348631,"accession_number":"0001193125-22-215003","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"RxSight files $200M shelf registration and enters $50M ATM equity offering with BofA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed $200M shelf registration on Form S-3 covering common stock, preferred, debt, warrants, and units.","Entered ATM agreement to sell up to $50M of common stock through BofA Securities.","Registration statement is not yet effective; no sales can occur until SEC declares it effective.","BofA will receive 3% commission on gross proceeds from ATM sales; Company may also sell directly to BofA as principal.","Either party may terminate the ATM agreement with three days' written notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348630,"accession_number":"0000950170-22-015514","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $11.4M (+132% YoY); raises FY22 guidance to $44-46M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.4M (+132% YoY); sold 49 LDDs, installed base 294 (+126% YoY).","LAL procedure volumes 5,400 (+196% YoY).","Net loss $(16.7)M ($0.61/share); adjusted loss $(13.8)M ($0.50/share).","Raised FY22 revenue guidance to $44-46M (95-104% growth); gross margin guidance to 37-38%.","Cash and investments $128.6M; long-term debt $39.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":20301000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348629,"accession_number":"0000950170-22-012611","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"RxSight receives FDA request for additional info on lower-cost LDD; expects no timeline impact","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requested additional information for approval of lower-cost-to-manufacture Light Delivery Device (LDD).","Commercial sale of the lower-cost LDD not planned until 2023; company believes it can meet the timeline.","Lower-cost LDD has the same functionality as the currently marketed LDD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365364,"accession_number":"0000950170-22-011072","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RxSight stockholders re-elect three Class I directors and ratify EY as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ron Kurtz, J. Andy Corley, and Juliet Tammenoms Bakker re-elected as Class I directors with over 18.3M votes for each.","Ernst & Young LLP ratified as independent auditor for FY2022 with 22,575,352 votes for, 2,827 against, 118,118 abstain.","Approximately 82.6% of outstanding shares (22.7M of 27.5M) were represented at the virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365363,"accession_number":"0000950170-22-007845","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q1 revenue up 157% to $8.9M; raises 2022 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.9M (+157% YoY); LDD sales 40 units (+208%), installed base 246 (+134%).","Net loss $17.6M ($0.64/share); adjusted net loss $14.9M ($0.54/share).","2022 revenue guidance raised to $41.5-45.5M from $40-44M, implying 84-101% annual growth.","Amended Oxford Finance loan: extends draw periods for remaining $20M, interest-only period to 2025.","Procedure volumes: 4,166 LALs sold (+166% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":8942000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384967,"accession_number":"0000950170-22-003130","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q4 revenue $8.4M (+71% YoY); FY22 guidance $40-44M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $8.4M, up 71% YoY; FY2021 revenue $22.6M, up 54% YoY.","Q4 net loss $(15.7)M ($(0.58)/diluted share); adjusted net loss $(12.8)M ($(0.47)/share).","Sold 45 LDDs in Q4, installed base 206; 2,959 LALs sold in Q4.","Cash and investments $159.3M; long-term debt $39.8M as of Dec 31, 2021.","FY2022 revenue expected $40-44M; gross margin 35-36%; OpEx $86-90M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384966,"accession_number":"0000950170-22-000156","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"RxSight Q4 revenue ~$8.4M (+71% YoY); full year 2021 revenue ~$22.6M (+54% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue ~$8.4M, up 71% YoY; sold 45 LDDs (installed base 206) and 2,959 LALs.","FY 2021 revenue ~$22.6M, up 54% YoY; 114 LDDs and 8,328 LALs sold.","Cash, equivalents and short-term investments ~$159.3M as of Dec 31, 2021.","CEO Ron Kurtz cites continued adoption and ActivShield rollout as growth drivers for 2022.","Results are preliminary; audited Q4 and FY 2021 results expected in early March."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":22593000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384965,"accession_number":"0000950170-22-000038","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RxSight appoints Shweta Maniar and Dr. Tamara Fountain to board; expands to nine members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 9; Maniar (Google Cloud) and Dr. Fountain (ophthalmologist) effective Dec 31, 2021 and Jan 1, 2022.","Maniar serves on Governance/Nominating Committee; receives $45k annual retainer, $5k committee fee, initial RSUs valued at $217,500.","Dr. Fountain, 2021 President of American Academy of Ophthalmology, serves on Audit Committee; receives no compensation during 2022 per AAO policy.","Outside Director Compensation Policy updated: annual cash retainer raised from $40k to $45k; initial RSU award increased from $125k to $217,500."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402840,"accession_number":"0000950170-21-004078","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q3 2021 revenue $5.8M (+39% YoY); net loss $12.7M; FY revenue guidance $21.0-$21.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $5.8M, up 39% YoY and 18% QoQ; 31 LDDs sold, installed base 161.","Net loss $(12.7)M ($(0.68)/share) vs net income $5.9M in Q3 2020; adjusted net loss $(12.2)M ($(0.65)/share).","Cash and investments $168.3M; long-term debt $39.6M as of Sep 30, 2021.","FY 2021 revenue guidance $21.0M-$21.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":14167000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421761,"accession_number":"0000950170-21-001738","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $4.9M (+81% YoY); net loss $(13.5)M; raises ~$120M in July IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.9M (+81% YoY); sold 25 LDDs and 1,825 LALs during Q2.","Net loss $(13.5)M ($(3.28)/share basic); adjusted net loss $(13.3)M ($(3.24)/share).","Gross loss $(0.8)M due to $1.7M inventory reserve for updated LAL with ActivShield.","Completed IPO in July 2021 raising ~$120M net proceeds; cash & equivalents $61.7M at June 30.","FDA approval and launch of LAL with ActivShield technology; new VP of U.S. Sales appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-09T23:59:59+00:00|421761"}